title: Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use.
abstract: In the drive to develop drugs with well-characterized and clinically monitorable safety profiles, there is incentive to expand the repertoire of safety biomarkers for toxicities without routine markers or premonitory detection. Biomarkers in blood are pursued because of specimen accessibility, opportunity for serial monitoring, quantitative measurement, and the availability of assay platforms. Cytokines, chemokines, and growth factors (here referred to collectively as cytokines) show robust modulation in proximal events of inflammation, immune response, and repair. These are key general processes in many toxicities; therefore, cytokines are commonly identified during biomarker discovery studies. In addition, multiplexed cytokine immunoassays are easily applied to biomarker discovery and routine toxicity studies to measure blood cytokines. However, cytokines pose several challenges as safety biomarkers because of a short serum half-life; low to undetectable baseline levels; lack of tissue-specific or toxicity-specific expression; complexities related to cytokine expression with multiorgan involvement; and species, strain, and interindividual differences. Additional challenges to their application are caused by analytical, methodological, and study design-related variables. A final consideration is the strength of the relationship between changes in cytokine levels and the development of phenotypic or functional manifestations of toxicity. These factors should inform the integrated judgment-based qualification of novel biomarkers in preclinical, and potentially clinical, risk assessment. The dearth of robust, predictive cytokine biomarkers for specific toxicities is an indication of the significant complexity of these challenges. This review will consider the current state of the science and recommendations for appropriate application of cytokines in preclinical safety assessment.
authors.affiliation: Safety Assessment, Genentech, Inc., South San Francisco, California 94080, USA. tarrant.jacqueline@gene.com
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Tarrant
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood*; D016207:Cytokines / Q000097:blood*; D018570:Risk Assessment; D018675:Toxicity Tests
chemical_list: D015415:Biomarkers; D016207:Cytokines
references.citation: J Clin Pharmacol. 2005 Oct;45(10):1165-71
references.pmid: 16172181
references.citation: J Immunol Methods. 2009 Jan 1;340(1):55-64
references.pmid: 18983846
references.citation: Exp Hematol. 2002 Nov;30(11):1227-37
references.pmid: 12423675
references.citation: Arch Dermatol Res. 2000 Aug;292(8):391-6
references.pmid: 10994773
references.citation: Methods. 2006 Apr;38(4):294-303
references.pmid: 16481197
references.citation: Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1186-92
references.pmid: 15321784
references.citation: N Engl J Med. 2006 Sep 7;355(10):1018-28
references.pmid: 16908486
references.citation: Ann Intern Med. 1998 Jan 15;128(2):127-37
references.pmid: 9441573
references.citation: Cytometry B Clin Cytom. 2009 May;76(3):159-68
references.pmid: 18823005
references.citation: J Clin Periodontol. 2003 Dec;30(12):1046-52
references.pmid: 15002890
references.citation: Clin Pharmacol Ther. 2001 Mar;69(3):89-95
references.pmid: 11240971
references.citation: PLoS One. 2007 Jul 18;2(7):e621
references.pmid: 17637837
references.citation: Blood. 1997 Oct 1;90(7):2541-8
references.pmid: 9326219
references.citation: Toxicology. 2008 Mar 20;245(3):219-23
references.pmid: 18280028
references.citation: Nat Immunol. 2009 Apr;10(4):333-9
references.pmid: 19295629
references.citation: Cytokine Growth Factor Rev. 2009 Feb;20(1):61-75
references.pmid: 19213592
references.citation: J Immunol. 2004 Mar 1;172(5):2731-8
references.pmid: 14978070
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1259-71
references.pmid: 19038585
references.citation: Cytokine. 2002 Sep 7;19(5):228-35
references.pmid: 12393169
references.citation: Biomarkers. 2010 Mar;15(2):140-8
references.pmid: 19848603
references.citation: Nature. 2008 Jul 24;454(7203):428-35
references.pmid: 18650913
references.citation: Eur J Obstet Gynecol Reprod Biol. 1999 Apr;83(2):213-7
references.pmid: 10391535
references.citation: Toxicol Pathol. 2008 Oct;36(6):840-9
references.pmid: 18776166
references.citation: Cytokine Growth Factor Rev. 2009 Feb;20(1):43-59
references.pmid: 19038572
references.citation: J Immunol Methods. 2009 Oct 31;350(1-2):161-70
references.pmid: 19732777
references.citation: Transfus Med. 2001 Dec;11(6):403-17
references.pmid: 11851938
references.citation: Cardiovasc Res. 2007 May 1;74(2):213-22
references.pmid: 17382916
references.citation: Toxicol Pathol. 2006;34(1):39-51
references.pmid: 16507543
references.citation: Clin Pharmacol Ther. 1999 Jun;65(6):615-29
references.pmid: 10391667
references.citation: Cancer Biomark. 2005;1(1):29-39
references.pmid: 17192030
references.citation: Shock. 2007 Mar;27(3):238-41
references.pmid: 17304103
references.citation: Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4265-73
references.pmid: 16857801
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3450-6
references.pmid: 19064561
references.citation: J Immunotoxicol. 2009 Mar;6(1):1-10
references.pmid: 19519157
references.citation: Clin Vaccine Immunol. 2008 Jan;15(1):42-8
references.pmid: 18003817
references.citation: Nat Rev Immunol. 2009 Oct;9(10):692-703
references.pmid: 19859064
references.citation: FEBS Lett. 2007 May 15;581(10):2017-21
references.pmid: 17470370
references.citation: Annu Rev Med. 2008;59:1-12
references.pmid: 18186700
references.citation: Shock. 2002 Apr;17(4):322-8
references.pmid: 11954835
references.citation: Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21407-12
references.pmid: 19955445
references.citation: Cytometry B Clin Cytom. 2004 Sep;61(1):35-9
references.pmid: 15351980
references.citation: J Clin Invest. 2008 Apr;118(4):1405-16
references.pmid: 18357346
references.citation: Front Biosci (Landmark Ed). 2009 Jan 01;14:540-51
references.pmid: 19273084
references.citation: Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):209-34
references.pmid: 17428152
references.citation: J Transl Med. 2004 Jun 2;2(1):17
references.pmid: 15175100
references.citation: Cell. 2008 Jan 25;132(2):259-72
references.pmid: 18243101
references.citation: Biochem Biophys Res Commun. 2002 Oct 4;297(4):700-13
references.pmid: 12359210
references.citation: News Physiol Sci. 2000 Dec;15:298-303
references.pmid: 11390930
references.citation: Mol Biol Evol. 1999 Feb;16(2):180-93
references.pmid: 10028286
references.citation: Pharm Res. 2005 Apr;22(4):499-511
references.pmid: 15846456
references.citation: Clin Pharmacol Ther. 2009 Mar;85(3):247-58
references.pmid: 19177065
references.citation: Nat Immunol. 2008 Apr;9(4):353-9
references.pmid: 18349815
references.citation: Transpl Immunol. 2005 Jun;14(2):77-82
references.pmid: 15935297
references.citation: Toxicol Appl Pharmacol. 2005 Feb 15;203(1):62-87
references.pmid: 15694465
references.citation: J Pharm Biomed Anal. 2005 Jan 4;36(5):1037-44
references.pmid: 15620530
references.citation: Clin Chem. 2009 Jun;55(6):1092-9
references.pmid: 19372187